Radium Ra 223 Dichloride Therapy in the Private Practice Environment.

Abstract

Independent urology groups are currently availing themselves of the numerous life-extending therapies that have been US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC). As they bolster their groups’ capabilities to impact and extend patient lives, they are expanding their account offerings by integrating infusion suites (sipuleucel-T), dispensing pharmacies (abiraterone, enzalutamide), and hot laboratories (radium-223 [223Ra]). Each of these medicines has a unique mechanism of action that allows physicians to tailor treatment to an individual’s disease characteristics.